This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

ZOSTAVAX is indicated for

  • Prevention of herpes zoster ("zoster" or shingles) and herpes zoster-related post-herpetic neuralgia (PHN) in the UK
  • Immunisation of individuals who are 50 years of age or older

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-CIN-00208 | Date of Preparation: June 2020